TY - JOUR
T1 - Vitamin C demand is increased after total knee arthroplasty
T2 - a double-blind placebo-controlled-randomized study
AU - Behrend, Henrik
AU - Lengnick, Harald
AU - Zdravkovic, Vilijam
AU - Ladurner, Andreas
AU - Rudin, Diana
AU - Erschbamer, Matthias
AU - Joerger, Markus
AU - Kuster, Markus
PY - 2019/4
Y1 - 2019/4
N2 - Purpose: This study was designed to determine whether perioperative supplementation of vitamin C (VC) improves range of motion (ROM) and reduces the risk of arthrofibrosis (AF) following total knee arthroplasty (TKA). Methods: Ninety-five patients undergoing TKA were randomized to either oral VC (1000 mg daily) or placebo for 50 days (48 VC group, 47 placebo group). The effect of VC supplementation was tested on ROM, AF, WOMAC, FJS-12, and VC plasma concentrations (VCc). VCc were analyzed in both patient groups before surgery, 4 and 7 days after surgery. Results: ROM at 1 year was not different between study groups. The prevalence of AF was 5 of 48 (10.4%) in the VC group compared to 11 of 47 (23.4%) in the placebo group (p = 0.09). VCc decreased post-operatively in the placebo group (49–12 µmol/l on day 7, p < 0.001), but not in the VC group (53–57 µmol/l). Patients with a perioperative drop of VCc ≥ 30 µmol/l developed significantly more AF at 1 year compared to patients with a VCc drop of < 30 µmol/l (p = 0.007). Conclusions: TKA results in VC depletion. Perioperative VC supplementation prevents VCc drop in most patients undergoing TKA and may lower the incidence of AF. The clinical relevance of this study is that VC supplementation seems to be a cheap and safe adjunct to improve functional outcome after TKA. Level of evidence: I. Trial registry: The study was registered at the ISRCTN registry with study ID ISRCTN40250576.
AB - Purpose: This study was designed to determine whether perioperative supplementation of vitamin C (VC) improves range of motion (ROM) and reduces the risk of arthrofibrosis (AF) following total knee arthroplasty (TKA). Methods: Ninety-five patients undergoing TKA were randomized to either oral VC (1000 mg daily) or placebo for 50 days (48 VC group, 47 placebo group). The effect of VC supplementation was tested on ROM, AF, WOMAC, FJS-12, and VC plasma concentrations (VCc). VCc were analyzed in both patient groups before surgery, 4 and 7 days after surgery. Results: ROM at 1 year was not different between study groups. The prevalence of AF was 5 of 48 (10.4%) in the VC group compared to 11 of 47 (23.4%) in the placebo group (p = 0.09). VCc decreased post-operatively in the placebo group (49–12 µmol/l on day 7, p < 0.001), but not in the VC group (53–57 µmol/l). Patients with a perioperative drop of VCc ≥ 30 µmol/l developed significantly more AF at 1 year compared to patients with a VCc drop of < 30 µmol/l (p = 0.007). Conclusions: TKA results in VC depletion. Perioperative VC supplementation prevents VCc drop in most patients undergoing TKA and may lower the incidence of AF. The clinical relevance of this study is that VC supplementation seems to be a cheap and safe adjunct to improve functional outcome after TKA. Level of evidence: I. Trial registry: The study was registered at the ISRCTN registry with study ID ISRCTN40250576.
KW - Arthrofibrosis
KW - Forgotten Joint Score-12
KW - Total Knee Arthroplasty (TKA)
KW - Total Knee Replacement (TKR)
KW - Vitamin C plasma levels
UR - http://www.scopus.com/inward/record.url?scp=85049143151&partnerID=8YFLogxK
U2 - 10.1007/s00167-018-5030-3
DO - 10.1007/s00167-018-5030-3
M3 - Article
C2 - 29955932
AN - SCOPUS:85049143151
VL - 27
SP - 1182
EP - 1188
JO - Knee Surgery, Sports Traumatology, Arthroscopy
JF - Knee Surgery, Sports Traumatology, Arthroscopy
SN - 0942-2056
IS - 4
ER -